Loading...

ALXO ALX ONCOLOGY HOLDINGS INC Management Changes 8-K Filing

LX N

LX

ALX ONCOLOGY HOLDINGS INC

(ALXO)

2025 8-K

Financial Results Report

Management Changes

Financial Statements

Notice of Delisting

Financial Results

Workforce Reduction

Management Changes

Equity Incentive Plan

Management Changes

Management Change

Earnings Reports

Appointment of Director and...

Annual Meeting of Stockholders

Earnings Reports

Resignation of Directors

Financial Results Announcement

Loan Agreement Amendment

Financial Results Announcement

Underwriting Agreement for ...

Earnings Reports

Study Protocol and Interim ...

Financial Results Announcement

Amended and Restated Bylaws

Earnings Reports

FDIC Receivership

Financial Results Announcement

External Links:

On September 11, 2025, ALX Oncology Holdings announced the resignation of Dr. Barbara Klencke from the Board effective September 17, 2025, and reappointed Dr. Alan Sandler to the Board, effective September 26, 2025. The company also regained compliance with Nasdaq's minimum bid price requirement, achieving a closing bid price of $1.00 or greater for ten consecutive days from August 21 to September 4, 2025.

AI Assistant

ALX ONCOLOGY HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.